Skip to Content
Merck
CN

30553

Supelco

Samarium(III) ionophore I

Selectophore™

Synonym(s):

Glipizide, 1-Cyclohexyl-3-{4-[2-(5-methylpyrazine-2-carboxamido)ethyl]phenylsulfonyl}urea

Sign Into View Organizational & Contract Pricing

Select a Size

About This Item

Empirical Formula (Hill Notation):
C21H27N5O4S
CAS Number:
29094-61-9
Molecular Weight:
445.54
EC Number:
249-427-6
MDL number:
MFCD00072159
UNSPSC Code:
26111700
PubChem Substance ID:
24858438

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

product line

Selectophore™

SMILES string

Cc1cnc(cn1)C(=O)NCCc2ccc(cc2)S(=O)(=O)NC(=O)NC3CCCCC3

InChI

1S/C21H27N5O4S/c1-15-13-24-19(14-23-15)20(27)22-12-11-16-7-9-18(10-8-16)31(29,30)26-21(28)25-17-5-3-2-4-6-17/h7-10,13-14,17H,2-6,11-12H2,1H3,(H,22,27)(H2,25,26,28)

InChI key

ZJJXGWJIGJFDTL-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

General description

Visit our Sensor Applications portal to learn more.

Other Notes

Indicator electrode for the potentiometric determination of Sm(III) with EDTA

Legal Information

Selectophore is a trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M.R. Ganjali et al.
Sensors and Actuators B, Chemical, 89, 21-21 (2003)
K M Pantalone et al.
Diabetes, obesity & metabolism, 14(9), 803-809 (2012-04-11)
It remains uncertain if differences in mortality risk exist among the sulfonylureas, especially in patients with documented coronary artery disease (CAD). The purpose of this study was to assess the overall mortality risk of the individual sulfonylureas versus metformin in
Christina M Deusenberry et al.
Pharmacotherapy, 32(7), 613-617 (2012-05-10)
To identify the incidence of and risk factors associated with hypoglycemia in hospitalized patients taking sulfonylureas. Nested case-control study. Tertiary care academic medical center. Adults who received a sulfonylurea during hospitalization between November 1, 2008, and October 31, 2009. Case
Wilma Erhardt et al.
Clinical drug investigation, 32(3), 189-202 (2012-02-02)
The lack of adequate glycaemic control for patients with type 2 diabetes mellitus (T2DM), especially with existing second-line therapies, represents an unmet medical need. Of the newer therapies, the incretin-based medicines, such as saxagliptin, look promising to consolidate second-line pharmacotherapy.
Korbinian Löbmann et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 81(1), 159-169 (2012-02-23)
The objective of this study was to prepare a co-amorphous drug/drug combination between two BCS class II drugs, simvastatin (SVS) and glipizide (GPZ). This pharmacologically relevant combination of two drugs could produce a promising candidate for formulations intended for combination
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service